Pharma BD Deal Intelligence

Lexicon Genetics Incorporated / Coelacanth Corporation

2001 · Acquisition/Merger · $32M · Complete

Announcement Sentiment
75
Strongly positive

Stock-for-stock; created Lexicon Pharmaceuticals. Below $250M threshold but strategically notable: chemistry/ADME platform; Coelacanth clients included Pfizer, Roche, Novartis.

Key facts

See the full interactive analysis, sources & comparables →